FDA Inspection 1262276 — Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. — FEI 3013754451

The FDA completed an inspection of Alnylam Pharmaceuticals Inc. on February 25, 2025 in Cambridge, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
February 25, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Cambridge, MA (United States)

Citations

IDCFRDescription
184321 CFR 211.84(d)(2)Component written specification
187621 CFR 211.180(b)Record maintenance 1 year (except exempt OTC)
202621 CFR 211.192Quality control unit review of records